Overview
About Ophiomics
Precision Liver Medicine
At Ophiomics, we are building the future of precision liver care by combining AI and genomics to deliver transformative diagnostic solutions across the entire liver disease spectrum.
Our end products are clinical decision-support algorithms, powered by data generated from genomic-based in vitro diagnostic kits, analysing liquid and tissue biopsies. These kits are designed to feed the algorithms that guide life-saving clinical decisions.
We are an end-to-end company, uniquely capable of moving from:
• Biomarker discovery
• To algorithm development
• To assay prototyping and manufacturing in our ISO13485-certified pilot facility
• To clinical validation, regulatory approval, and go-to-market execution
Our model is built on a reusable, modular lab platform for rapid development of genomic tests, both liquid biopsy–based and tissue-based, allowing us to scale innovation efficiently while ensuring analytical and clinical robustness.
With a CE-marked product already in early adoption, and next-generation tests for early liver cancer detection in validation, Ophiomics is driving a shift toward personalized, data-driven liver healthcare.
At Ophiomics, we are building the future of precision liver care by combining AI and genomics to deliver transformative diagnostic solutions across the entire liver disease spectrum.
Our end products are clinical decision-support algorithms, powered by data generated from genomic-based in vitro diagnostic kits, analysing liquid and tissue biopsies. These kits are designed to feed the algorithms that guide life-saving clinical decisions.
We are an end-to-end company, uniquely capable of moving from:
• Biomarker discovery
• To algorithm development
• To assay prototyping and manufacturing in our ISO13485-certified pilot facility
• To clinical validation, regulatory approval, and go-to-market execution
Our model is built on a reusable, modular lab platform for rapid development of genomic tests, both liquid biopsy–based and tissue-based, allowing us to scale innovation efficiently while ensuring analytical and clinical robustness.
With a CE-marked product already in early adoption, and next-generation tests for early liver cancer detection in validation, Ophiomics is driving a shift toward personalized, data-driven liver healthcare.